Hunter Gillies

2.9k total citations · 1 hit paper
42 papers, 1.9k citations indexed

About

Hunter Gillies is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Hunter Gillies has authored 42 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 12 papers in Cardiology and Cardiovascular Medicine and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Hunter Gillies's work include Pulmonary Hypertension Research and Treatments (25 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers) and Heart Failure Treatment and Management (5 papers). Hunter Gillies is often cited by papers focused on Pulmonary Hypertension Research and Treatments (25 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers) and Heart Failure Treatment and Management (5 papers). Hunter Gillies collaborates with scholars based in United States, United Kingdom and Germany. Hunter Gillies's co-authors include Christiana Blair, Ronald J. Oudiz, Jean‐Luc Vachiéry, Vallerie V. McLaughlin, Marius M. Hoeper, Jonathan Langley, Lewis J. Rubin, Gérald Simonneau, Karen Miller and Adaani Frost and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Journal of Applied Physiology.

In The Last Decade

Hunter Gillies

40 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

2015 750 citations Nazzareno Galiè, Joan Albert Barberà et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hunter Gillies United States	19	1.4k	865	224	209	143	42	1.9k
Abdallah Alzoubi Jordan	15	727 0.5×	368 0.4×	54 0.2×	22 0.1×	161 1.1×	34	1.1k
Ute Seeland Germany	23	218 0.2×	1.2k 1.4×	103 0.5×	77 0.4×	113 0.8×	60	2.1k
Michelle Frits United States	20	257 0.2×	78 0.1×	128 0.6×	222 1.1×	279 2.0×	55	1.6k
M A Cathey United States	17	99 0.1×	149 0.2×	168 0.8×	240 1.1×	102 0.7×	19	2.6k
James M. Gray United States	14	157 0.1×	201 0.2×	209 0.9×	42 0.2×	60 0.4×	51	895
Tsuyoshi Suzuki Japan	18	115 0.1×	420 0.5×	117 0.5×	37 0.2×	89 0.6×	73	1.2k
Fu‐Wen Liang Taiwan	17	153 0.1×	139 0.2×	85 0.4×	73 0.3×	61 0.4×	106	1.1k
Clark Paramore United States	11	134 0.1×	339 0.4×	87 0.4×	73 0.3×	47 0.3×	26	1.1k
Beverly J. Spray United States	19	129 0.1×	263 0.3×	49 0.2×	77 0.4×	92 0.6×	64	1.4k
Mohamedtaki Abdulaziz Tejani United States	22	454 0.3×	57 0.1×	27 0.1×	154 0.7×	128 0.9×	80	1.7k

Countries citing papers authored by Hunter Gillies

Since Specialization

Citations

This map shows the geographic impact of Hunter Gillies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hunter Gillies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hunter Gillies more than expected).

Fields of papers citing papers by Hunter Gillies

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hunter Gillies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hunter Gillies. The network helps show where Hunter Gillies may publish in the future.

Co-authorship network of co-authors of Hunter Gillies

This figure shows the co-authorship network connecting the top 25 collaborators of Hunter Gillies. A scholar is included among the top collaborators of Hunter Gillies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hunter Gillies. Hunter Gillies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gillies, Hunter, Murali M. Chakinala, Benjamin T. Dake, et al.. (2024). IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension. Pulmonary Circulation. 14(1). e12352–e12352. 5 indexed citations

Gillies, Hunter, Ralph W. Niven, Benjamin T. Dake, et al.. (2022). AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. ERJ Open Research. 9(2). 433–2022. 21 indexed citations

Gillies, Hunter, et al.. (2021). Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Systems Neuroscience. 15. 698240–698240. 7 indexed citations

Nathan, Steven D., Kevin R. Flaherty, Marilyn K. Glassberg, et al.. (2020). A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis. CHEST Journal. 158(2). 637–645. 69 indexed citations

Nathan, Steven D., Kevin R. Flaherty, Ganesh Raghu, et al.. (2019). OPEN-LABEL DOSE-ESCALATION DATA FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (INO) IN SUBJECTS AT RISK OF PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS (PH-PF) ON LONG TERM OXYGEN THERAPY. CHEST Journal. 156(4). A2273–A2275. 1 indexed citations

Shapiro, Shelley, Fernando Torres, Jeremy Feldman, et al.. (2017). Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respiratory Medicine. 126. 84–92. 18 indexed citations

Coghlan, Gerry, Nazzareno Galiè, Joan Albert Barberà, et al.. (2016). Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases. 76(7). 1219–1227. 109 indexed citations

Fischer, Aryeh, Christopher P. Denton, Marco Matucci‐Cerinic, et al.. (2016). Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial. Respiratory Medicine. 117. 254–263. 27 indexed citations

Galiè, Nazzareno, Joan Albert Barberà, Adaani Frost, et al.. (2015). Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine. 373(9). 834–844. 750 indexed citations breakdown →

10.

Gomberg‐Maitland, Mardi, Robert Schilz, Anuj Mediratta, et al.. (2015). Phase I Safety Study of Ranolazine in Pulmonary Arterial Hypertension. Pulmonary Circulation. 5(4). 691–700. 28 indexed citations

11.

Raghu, Ganesh, Steven D. Nathan, Jürgen Behr, et al.. (2015). Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal. 46(5). 1370–1377. 105 indexed citations

12.

Rubin, Lewis J., Joan Albert Barberà, Adaani Frost, et al.. (2014). Upfront Combination Therapy With Ambrisentan and TadalafilIin Treatment Naive Patients With Pulmonary Arterial Hypertension (PAH): Subgroup Analyses by Functional Class (FC), Etiology, and Region From the AMBITION Study. CHEST Journal. 146(4). 339A–339A. 3 indexed citations

13.

Maron, Bradley A., Aaron B. Waxman, Alexander R. Opotowsky, et al.. (2013). Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials). The American Journal of Cardiology. 112(5). 720–725. 72 indexed citations

14.

Fritz, Jason S., Christiana Blair, Ronald J. Oudiz, et al.. (2013). Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension. CHEST Journal. 143(2). 315–323. 73 indexed citations

15.

Venitz, Jürgen, et al.. (2011). Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. The Journal of Clinical Pharmacology. 52(12). 1784–1805. 52 indexed citations

16.

Oudiz, Ronald J., et al.. (2011). Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension: 3-Year Outcome. CHEST Journal. 140(4). 742A–742A. 5 indexed citations

17.

Vachiéry, Jean‐Luc, Sandrine Huez, Hunter Gillies, et al.. (2010). Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. British Journal of Clinical Pharmacology. 71(2). 289–292. 54 indexed citations

18.

Jackson, Graham, Hunter Gillies, & I. Osterloh. (2005). Past, present, and future: a 7-year update of Viagra® (sildenafil citrate). International Journal of Clinical Practice. 59(6). 680–691. 64 indexed citations

19.

Gillies, Hunter, David Roblin, & Graham Jackson. (2002). Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. International Journal of Cardiology. 86(2-3). 131–141. 57 indexed citations

20.

Gillies, Hunter, et al.. (1996). Pseudoephedrine is without ergogenic effects during prolonged exercise. Journal of Applied Physiology. 81(6). 2611–2617. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact